Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

Medientyp: E-Artikel
Titel: Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)
Beteiligte: Gooskens, Saskia L.M.; Oranje, Arnold P.; van Adrichem, Leon N.A.; de Waard‐van der Spek, Flora B.; den Hollander, Jan C.; van de Ven, Cees P.; van den Heuvel‐Eibrink, Marry M.
Erschienen: Wiley, 2010
Erschienen in: Pediatric Blood & Cancer
Sprache: Englisch
DOI: 10.1002/pbc.22494
ISSN: 1545-5009; 1545-5017
Schlagwörter: Oncology ; Hematology ; Pediatrics, Perinatology and Child Health
Entstehung:
Anmerkungen:
Beschreibung: <jats:title>Abstract</jats:title><jats:p>Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet‐derived growth factor β (<jats:italic>PDGFβ</jats:italic>) with the collagen type 1α1 (<jats:italic>COL1α1</jats:italic>) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome. Pediatr Blood Cancer. 2010;55:369–373. © 2010 Wiley–Liss, Inc.</jats:p>

Nur in Feld suchen: